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Summary
The aim of this field study was to determine the efficacy of vaccination against
highly pathogenic avian influenza (HPAI) virus strain H5N1 in Indonesia. A
limited, prototype clinical trial was performed using a standardised treatment
group, in which poultry flocks were vaccinated at least twice with a selected
H5N1 vaccine, and a control group comprising flocks treated with non-
standardised procedures chosen by the farmer. Each group consisted of six
flocks comprising either layers or native chickens. Haemagglutination inhibition
(HI) antibody levels were determined by regular serum sampling, and outbreak
surveillance relied on non-AI-vaccinated sentinel birds. After three vaccinations
high antibody titres were produced in the treatment group, and the percentage
of layers with an HI titre > 40 was approximately 90%. Although no conclusions
can be drawn regarding reduction of virus transmission, this study demonstrated
that 11 farms remained free from AI during the observation period, and that a
surveillance programme based on differentiating infected from vaccinated
animals (DIVA) can be implemented.
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Introduction
In 1997 an outbreak in Hong Kong of highly pathogenic
avian influenza (HPAI) strain H5N1 was reported to the
World Organisation for Animal Health (OIE) (22). Since
then, the virus has spread to many other countries in
Southeast Asia, Africa and Europe (2, 3). Outbreaks are
controlled by stamping out infected poultry, sometimes
followed by pre-emptive culling of contiguous flocks (11).
In Europe, Malaysia, Japan, South Korea and Thailand, this
strategy was successful, as the number of poultry outbreaks
remained rather limited, and affected countries were
declared free from the virus (3, 22). In some countries,
such as China, Vietnam and Indonesia, the virus spread
rapidly and many regions have become endemically
infected. The fear of a human pandemic (20), but also
concern about food security and protection of livelihoods
are important drivers for various organisations, such as the
Food and Agriculture Organization of the United Nations
(FAO), the World Health Organization (WHO), and the
United States Agency for International Development
(USAID), to participate in the control of HPAI in these
affected countries. Control strategies are being developed,
and surveillance programmes such as participatory disease
surveillance and response (PDS/R) (7) have been
implemented. Despite all such efforts, the disease is still
present, and human cases of H5N1 infection are still being
reported (21).
In endemically affected areas it is not feasible to apply pre-
emptive culling or a stamping-out strategy on a large scale
because many flocks are affected. Poultry farmers in these
areas lose income when their flock is infected, either owing
to reduced production or to increased mortality of their
poultry. Consequently, the disease in these countries is
mainly controlled by vaccination, using various types 
of vaccines, with the aim of preventing production losses if
HPAI occurs within a flock. However, farmers are still
confronted with outbreaks, even in birds on vaccinated
farms. Explanations that have been given are the use 
of poor quality vaccines or improper vaccination 
technique (1).
The question is, therefore, whether it is possible to
eradicate the virus by means of a proper vaccination
schedule using adequate vaccines, or whether the
application of vaccines will induce clinical protection for
poultry but will facilitate silent spread of the infection and
human exposure to the virus. Experimental studies have
shown that various vaccines (either heterologous or
homologous) are able to induce good clinical protection
against a challenge infection with H5N1 strains of HPAI (5,
8, 14, 15, 18). It is, however, questionable whether
experimental data can be extrapolated to the field, because
vaccination is often less effective when applied under field
conditions. Field data from Vietnam have shown that the
number of human cases of AI decreased following the
wide-scale application of vaccines (21). However, whether
this reduction was attributable to the vaccination
campaign, or to increased biosecurity measures or public
awareness, has not been established, because no control
group was included. It remains, therefore, unclear whether
vaccination can be effective with respect to reduction of the
number of outbreaks. 
In Indonesia, a large number of human cases have been
reported and the virus is still circulating despite the wide
application of vaccines. The control and surveillance
programme for AI in this country should therefore be
improved, as also indicated by the Indonesian government.
Using current surveillance data, the effectiveness of
vaccination in the field has been doubted, as suggested by
low coverage and low haemagglutination inhibition (HI)
antibody titres. However, the basic question is whether
flocks were not vaccinated properly or whether the
vaccines were of insufficient quality. Moreover, it has been
questioned whether vaccination could reduce horizontal
transmission of AI between vaccinated flocks. Finally, a
good surveillance system for AI in vaccinated poultry
flocks in Indonesia has been lacking. 
Therefore, a limited, prototype clinical trial was carried out
to measure antibody titres induced by vaccination, 
the success of immune coverage within flocks, and the
reduction in the number of outbreaks of H5N1 in
vaccinated flocks. The results should contribute 
to improving the control strategy and surveillance systems
in Indonesia, and may benefit the health status of both
poultry and humans. In addition, the difficulties with
implementing such a trial, and the use of a surveillance
system and vaccination campaign in sectors three and four
of the poultry production industry are discussed in this
paper. (The FAO has grouped all systems of poultry
production into four operational levels – sector one:
industrial, integrated farms with a high level of biosecurity;
sector two: non-integrated farms with moderate to high
biosecurity levels; sector three: small and medium-scale
poultry farms with limited biosecurity; and sector four:
backyard poultry with no biosecurity measures in 
place [7]).
Materials and methods
Study area
The trial was carried out in three sub-districts within the
district of Sukabumi in the province of West Java on Java,
Indonesia. Selection criteria for these sub-districts
included: recent outbreaks of H5N1 HPAI in the area, the
presence of commercial layer flocks of sector three,
adequate veterinary infrastructure, and access to laboratory
facilities.
A survey was carried out by the Centre for Indonesian
Veterinary Analytical Studies (CIVAS), an Indonesian non-
governmental organisation, to locate poultry flocks, and to
provide technical data on these farms. The minimum
number of flocks to be included in this clinical trial to
provide sufficient power to demonstrate a difference in
effectiveness between a treatment and a control group was
calculated to be approximately 200, with 100 flocks per
group. As expected, the number of flocks in the selected
sub-districts was not sufficient to meet this requirement.
Therefore, the trial was initiated with a lower number of
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flocks. It was considered a demonstration project to gain
insight into the adequacy of laboratory procedures, to
improve vaccination coverage and surveillance
programmes, to build experience in the design and
implementation of vaccination and surveillance
programmes, to extend the ability to conduct field
research, and to contribute to capacity building in
Indonesia.
Criteria for inclusion of farms
The farms to be included in the trial were those producing
commercial layers and native-breed broilers, as the
production cycles of these two types would last long
enough for the chickens to develop a vaccine-induced
immune response. The production period of the layer
flocks was approximately 1 year and that of the native
broiler chickens was 3 months. Farms of sectors one and
two were not included because government veterinarians
generally do not have access to these farms. 
Two groups were formed: a treatment group and a control
group. These two groups differed in the vaccination
programme for AI, as described in the next paragraph. In
the treatment group there were more flocks than there
were farms: either there were more sheds on the farm or
the production period of native chickens was shorter than
the duration of the trial, so when a flock was slaughtered it
was replaced by a new flock. The owners might have been
more interested in participating a second time than owners
of the control native farms.
Vaccine and vaccination scheme
Treatment group
The vaccine used for the treatment group was a locally
produced commercially available vaccine based on the
HPAI H5N1 seed strain A/chicken/Legok/03. The vaccine,
Medivac AI vaccine, was produced by PT Medion
(Bandung, Indonesia) according to OIE guidelines (22).
Medivac AI contains field isolated avian influenza virus of
H5 subtype. The inactivated viruses are emulsified in
mineral oil adjuvant to enhance and prolong the efficacy of
the vaccine. Each dose contains at least 50 times the 50%
protective dose (PD50) (5).
The vaccine was injected intramuscularly into the leg
according to the recommendation of the manufacturer. The
vaccination was carried out by farm staff or by para-
veterinarians of the Dinas Peternakan (Government
Livestock Services) supervised by veterinarians from
CIVAS.
The aim was to vaccinate layers in the treatment group
three times, at 4, 10 and 17 weeks of age. Native chicken
broilers were vaccinated twice, at 10 and 30 days old
(Table I).
Backyard (sector four) poultry within a radius of 1 km
around each flock in the treatment group were vaccinated
every four months by Dinas Peternakan and CIVAS staff
using the same vaccine batches as for flocks of the
treatment group. This area is referred to as ‘the ring’. The
aim of vaccination in this area was to reduce the chance of
infection occurring in chickens near to a flock in the
treatment group, which could increase the risk of
introduction of virus into the study flock. This is not
unlikely, because the biosecurity level of these flocks is 
not very high. 
Control group
It was considered unethical to include a group of
intentionally unvaccinated flocks in this trial, as the area
was endemically infected. Any introduction of virus would
probably result in high mortality, and a high virus load,
resulting in loss of income for the owner, and increased
risk of exposure for humans. The control group consisted
of flocks that were vaccinated by the farmers according to
their own vaccination scheme. Vaccines were purchased by
the farmers and applied by farm staff. Vaccination
schedules on control farms differed. Layer flocks were
generally vaccinated twice, at 4 and at 16 to 18 weeks of
age; native chicken flocks were vaccinated once at 10 days
of age. Information about the vaccines used was either not
provided by the farmers or was incomplete. The vaccines
could include any vaccine available, either legally or
illegally, including Medivac AI. No ring vaccination around
farms in this group was applied by Dinas Peternakan or
CIVAS.
Surveillance
Two variables were determined:
– antibody responses after vaccination 
– the number of H5N1 outbreaks in each flock.
In a vaccinated population, the surveillance strategy
should be based on virological and/or serological methods
and clinical surveillance (22). In flocks where homologous
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Table I
Vaccination and sampling scheme for flocks in the treatment
group
Farm type Vaccination at age Sampling at age
Layer 4, 10, 17 weeks 8, 14, 21 weeks
Native chicken 10, 30 days 28, 70 days
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AI vaccines are used, the OIE (22) suggests a surveillance
system based on the DIVA principle. A DIVA strategy is
defined as one that differentiates vaccinated from infected
animals (12, 19), and it involves the use of accompanying
serological tests, or sentinel birds that are not vaccinated
against AI (hereafter referred to as ‘sentinels’) (22). Such a
surveillance system is, however, currently lacking in
Indonesia.
As a homologous vaccine was used, at least in the
treatment group, the surveillance had to be based on
sentinels, according to the DIVA principle as described by
the OIE (22). This excludes the possible contribution of
infection to antibody titres and allows detection 
of incursions and subsequent outbreaks of H5N1 
virus strains.
Sentinels were placed in each flock in both the treatment
and control groups. The sentinels originated from the same
farm as the one on which they were placed. The sentinel
birds in the native chicken flocks were labelled with a
metal ring around one leg, and were easily identifiable in
the flock; the birds in the layer flocks were housed in cages,
as were the other birds in the flock. The sentinels received
equivalent treatment with respect to vaccinations against
all diseases except AI. Within each shed, 10 to 50 sentinels
were maintained, depending on the number of birds in
each shed. The sentinels were housed in the same way as
the other birds: either they could mingle freely within the
group (native chickens) or were put in individual cages
(layers). Serum samples were taken from the sentinels at
the time of first vaccination of the flock, in order to
demonstrate the absence of antibodies against H5 at the
start of the trial. It was assumed that birds were not
infected with H5N1 if clinical signs were absent.
Sampling
The farms included in the trial were visited regularly by
CIVAS staff members for sampling and clinical inspection.
Dead sentinels were reported immediately by the owners to
CIVAS, and swab samples were collected from the trachea
and cloaca of every dead sentinel bird. If sentinels were
found dead by CIVAS, or if these birds or other birds in the
flock showed signs of AI, the same procedure was
followed. Swabs were placed in a tube containing transport
medium and were stored at 4ºC during transport to the
laboratory, which took place within 24 h after collection.
Serum samples were collected regularly to monitor
vaccine-induced antibodies and introduction of H5N1
virus. Serum samples from 20 randomly selected
vaccinated birds were collected on the days on which
flocks of the treatment group were vaccinated; samples
were collected from flocks of the control group at similar
times. Layers were also sampled one month after the last
vaccination; native chickens were sampled at the end of the
production period (at the age of 2 to 3 months). Serum
samples from ten randomly selected sentinels were
collected at the same sampling points to demonstrate that
they were still seronegative for H5, and to monitor
subclinical infections with low pathogenic avian influenza
(LPAI) H5 strains. At the end of the production period,
sentinels were swabbed and serum samples were taken to
demonstrate the absence of infection with AI virus.
Two months after each vaccination of backyard chickens in
the ring around the flocks in the treatment group, serum
samples were taken from 20 randomly selected birds per
ring to monitor antibody titres.
Laboratory tests
The swabs were transported in medium to the Bbalitvet
reference laboratory in Bogor, Indonesia. The samples were
stored at –70ºC until they were tested for the presence 
of H5 AI antigen. A polymerase chain reaction (PCR) kit
(InvitrogenTM) (9) was used to detect H5 RNA in each
sample according to the manufacturer’s instructions.
Positive samples were cultured in embryonated specific
pathogen free (SPF) eggs according to the standard
procedures of Bbalitvet, which follow the method
described in chapter 2.1.14 of the OIE Manual 
of Diagnostic Tests and Vaccines for Terrestrial Animals
(Terrestrial Manual) (22).
The serum samples were tested in the provincial animal
health laboratory of West Java in Cikole. Blood samples
were centrifuged and serum was stored at 4ºC until tested.
Tests were carried out shortly after arrival of the samples in
the laboratory. The sera were tested by an HI test using
twofold dilutions according to the procedures described in
the Terrestrial Manual (22), using 4 haemagglutination
units (HAU) of H5N1 strain A/ch/Legok/03 as the antigen.
Erythrocytes from SPF chickens were provided by PT
Medion, Bandung. A positive and a negative serum sample
were included in each test, and tests were carried out in
duplicate. Titres were expressed as 2x of the serum dilution
that caused complete inhibition of agglutination (22). 
Results
Farms
A total of twelve farms were included in the trial. The
treatment group consisted of two layer and four native
chicken farms, and the control group contained four layer
and two native chicken farms. In the treatment group, for
reasons already discussed, more flocks than farms were
included and used for the calculation of the average titre
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(Table II). The treatment was not allocated randomly, as
some farmers were willing to cooperate only when they
could apply their own vaccination programme. These
farms became part of the control group.
Table II
Technical data from the flocks in the treatment and control
groups
Group Farm type Number of farms Total number of flocks*
Treatment Layer 2 5
Native chicken 4 9
Control Layer 4 4
Native chicken 2 2
* In the treatment group there were more flocks than there were farms: one layer farm 
had more sheds that were included. With respect to the native chicken farms, the
production period of poultry was shorter than the duration of the trial, so when a flock was
slaughtered it was replaced by a new flock
Serology
The average titre was based on samples with a titre >21. So-
called non-responders were not included in this
calculation. The vaccination coverage (percentage of birds
with a predefined titre) was calculated for a cut-off of 24
and for a cut-off of 25 (10).
Treatment group
In the layer farms, the average geometric titre of serum
after two vaccinations was 25.9 (standard deviation [SD]
21.7), and after the third vaccination it was 27.2 (SD 22.0).
The mean was based on samples from a total of five flocks
from two layer farms, collected in 2007. None of the
samples had a titre of 21, indicating that in these flocks no
non-responders were present after the second and third
vaccinations. The distribution of titres was more or less
normal (Fig. 1). Two birds out of a total of 120 birds
sampled from the treatment group had a titre below 24.
Assuming that a titre of 24 represented a positive response,
this finding means that the vaccine coverage, here defined
as the percentage of birds with a titre equal to or higher
than 24, was >95%. The vaccine coverage using a cut-off
value of 25 was approximately 90%.
In the native chicken flocks (4 farms; 9 flocks in total),
24% of the birds had a titre of 21 at the end of production,
after two vaccinations. We estimated the average titre of the
remaining 76% of the birds, which did respond (Fig. 2).
The average titre in these birds was 24.4 (SD 22.3). In this
group, 51% of samples had a titre above 24, thus a much
lower coverage was achieved, and this was exacerbated
because the number of non-responders was much higher
than among the layers in the treatment group.
Control group
The average titre of birds in layer flocks after the second
vaccination was 25.8 (SD 23.7). This calculation was based
on samples collected from chickens of all four layer farms.
In one of these flocks, very few sampled birds developed a
titre. In this flock a vaccine of unknown origin had been
used. The average titre in this particular flock was 20.4
(SD 20.9) with a coverage of 0%. The average titre of the
three other flocks was 27.6 (SD 22.2) with a coverage (at a
titre of 24) of approximately 93% after the second
vaccination.
The average coverage in the native chicken flocks was
50%. The average titre in the native chicken flocks in the
control group was 22.9 (SD 22.4).
Ring zone
The average titre in the 1 km ring around the flocks in the
treatment group after two vaccinations was 22.6 (SD 22.7).
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Fig. 1
Distribution of HI antibody titres in samples from layer 
flocks in the treatment group that were collected after two 
and three vaccinations
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Fig. 2
Distribution of HI antibody titres in samples from native chicken
flocks in the treatment group after two vaccinations, collected
at the end of the production period
The vaccination coverage (percentage of birds with a titre
of 24 or above) was 38%. The coverage estimated using this
cut-off titre in the 1 km ring around the flocks in the
control group was 12%.
Virus detection
An outbreak of H5 virus infection occurred on one farm in
the treatment group approximately 4 weeks after the
second vaccination, as demonstrated by a positive PCR test
and virus isolation in embryonated eggs. The farm had 
95 sheds containing poultry, of which five were included in
the trial. The outbreak seemed to have started in one of the
sheds containing growers that had not been included in 
the trial. Poultry in two sheds included in the trial were
affected 1 week after the second vaccination (aged 12 to 
13 weeks). The average titre just before virus introduction
was approximately 25.2 (SD 21.3); the percentage of samples
with a titre >24 was 80%. The other sheds in the trial were
culled at 57 to 62 weeks of age, and no additional
information about these sheds was available. The virus that
caused the outbreak was isolated from the sentinel birds
and was confirmed to be HPAI H5 by PCR. Preliminary
RNA sequence analysis performed at Bbalivet showed that
the strain was similar to A/Ch/WJ/PWT-WIJ/06, which was
isolated on Java in 2006 (13). No H5 virus was detected on
the other farms that participated in the trial.
Discussion
The aim of this study was to study the effectiveness of
vaccination against H5N1 AI under field conditions by
measuring antibody titres in the HI test and detecting
outbreaks of H5 virus infection. The vaccine coverage of a
flock was estimated from the titre values. Sentinel birds
that were not vaccinated against AI were used to record
major H5N1 outbreaks in the flocks included in the trial,
and were also necessary for correct interpretation of the
antibody titres. Without this DIVA surveillance system it is
impossible to be sure whether the measured titres result
from vaccination, infection with H5 subtype viruses, or a
combination of the two.
The average titre after two vaccinations of layers in the
treatment group was 25.9 and the coverage, here defined as
the percentage of samples with a titre of 24 or above, was
more than 95%. This trial demonstrates that, with locally
produced homologous vaccines, high antibody titres and a
high coverage could be reached, at least in layer flocks.
Philippa et al. (10) used a different cut-off value for vaccine
effectiveness. They used a titre of >40, a value that is
considered to be protective and to reduce virus replication
in humans, in a situation in which challenge experiments
were not ethical. For similar reasons Philippa et al. (10)
assumed that vaccinated zoo birds with a titre of 1:40 or
greater would be protected. After three vaccinations the
coverage obtained using this cut-off value was
approximately 90%. It would be helpful to have more data
on the relationship between titre and protection against
virus transmission, as has been described for Newcastle
disease (17).
An important aim of vaccination is to reduce the
transmission of virus within and between flocks. The
reproduction ratio R, the average number of secondary
cases caused by one infectious animal (6), is a frequently
used measure of transmission of pathogens. If R is larger
than one, the infection will spread. This measure can also
give an indication of the critical fraction of immune birds
that is required to prevent major outbreaks in a flock (6).
If the percentage of vaccinated birds in a flock is 1−1/R, the
virus can be eliminated by vaccination. For H5N1 virus
within a poultry flock the R has been estimated to be about
2.3 to 2.6 (16). From the reproduction ratio, the critical
fraction of immune birds is estimated to be approximately
60% if a perfect vaccine is used. Assuming that HI titres
>40 are sufficient to reduce the reproduction ratio to 0, the
coverage of 90% achieved in the layer flocks in 
the treatment group of this study seems to be sufficient. It
should be realised, however, that the vaccine is probably
not perfect, and R values may differ between flocks. A level
of coverage higher than 60% is therefore advisable. 
The titres of the samples from native chickens were lower,
and more birds on these farms did not have a detectable
titre. It has been suggested that native chickens may be less
responsive to vaccination. The lower responses were
explained by concurrent diseases or immunosuppressive
infections at the time of or after vaccination, but 
the underlying mechanism of the lower response needs to
be explored. It is necessary to study the transmission of 
the virus in native chickens using vaccination challenge
experiments under controlled conditions. 
An outbreak of AI occurred in one of the layer flocks in the
treatment group. It is believed that the outbreak started in
one of the sheds on the farm that was not included in the
treatment group. As a result of the increase in the number
of birds in the affected shed that were shedding virus, the
dose of virus to which the birds in the flock that were
included in the treatment group was exposed may have
been very high. The level of virus challenge was probably
much higher than that to which birds in sheds located in a
remote area would have been exposed. In addition, this
farm may have been infected by an antigenic mutant strain
like the A/Ch/WJ/PWT-WIJ/06 strain. Vaccination
challenge studies have shown that most vaccines currently
licensed in Indonesia do not provide optimal protection
against this strain (13). Based on preliminary sequencing,
the virus isolated from this flock was similar to the
A/Ch/WJ/PWT-WIJ/06 strain. Given that an outbreak
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occurred only in a flock of the treatment group, one could
infer at first sight that vaccination in this group was less
effective than in the control group. This cannot be
concluded, however. First, it is obvious that the number of
outbreaks is far too low to be of any statistical significance.
Second, farms were not randomly allocated to the two
groups, either treatment or control, because participation
was entirely voluntary. Therefore, we cannot exclude the
possibility that, among other factors, farm management
differed substantially between the two groups.
When monitoring HI antibodies induced by vaccination it
is essential to ensure that the antibodies are the result of
vaccination only and are not caused by infection with an
H5 subtype virus, or a combination of vaccination and
infection. The possible contribution of infection can only
be excluded by using the DIVA principle (12, 19). 
The DIVA strategy used in this trial was based on the use
of sentinel birds; we could not use antibodies against 
the neuraminidase protein because a homologous
neuraminidase vaccine was used. It seems reasonable to
assume that the risk of outbreaks of HPAI attributable 
to the presence of sentinels is negligible, as only a few birds
in each shed were sentinels. Moreover, direct contact
between the sentinels and the vaccinated birds did not
occur, as they were all housed in cages. Data from
transmission trials has shown that no indirect virus
transmission occurs (4); therefore it seems unlikely that the
sentinels on the outbreak farm initially contracted the
infection and were responsible for the subsequent
extensive spread of the virus. Many farmers are of the
opinion that sentinels are at high risk of infection with AI.
The level of knowledge of farmers and veterinarians with
respect to the risks inherent in the use of sentinels and the
value of adequate surveillance systems in the control of AI
should therefore be improved. This may contribute to 
the adoption of DIVA vaccination campaigns and
improvement of the current surveillance strategies.
The number of farms included in this study was much
lower than calculated for the power analysis. One of the
reasons was that farmers were reluctant to participate, and
much time and effort was expended on visiting farms and
informing the farmers of the trial. In addition to this, the
treatment was not allocated randomly, as some farmers
were willing to cooperate only when they could apply their
own vaccination programme. The programme set up to
inform farmers and try to convince them to join the trial
experienced difficulties, especially in convincing farmers to
implement the DIVA strategy using sentinel chickens.
Farmers were worried about the risk of these sentinels
being a source of infection to other chickens in the flock. 
The small sample size means that it is impossible to draw
conclusions about the effectiveness of vaccination in
relation to virus transmission between flocks, to perform
statistical analysis or to make statistical inferences from the
results of this trial. In addition, the owners of backyard
chickens did not always respond to the vaccination
campaign, and there was a lack of support from the
government of the villages. Moreover, flock owners were
not convinced that repeated vaccinations were necessary,
and were afraid that vaccination may lead to increased
mortality. The whole vaccination procedure was time
consuming because field officers had to catch many of the
chickens to be vaccinated.
Nevertheless, we learned important lessons from this trial
about the antibody responses that can be induced by
vaccination in the field, about the quality of the laboratory
test procedures, and finally about various aspects of the
organisation and implementation of a surveillance
programme in Indonesia. The surveillance system, based
on the DIVA principle, also showed that farms can remain
free from H5N1 virus during their production cycle. These
and other lessons can be of use for other organisations
involved in the planning and implementation of
surveillance and control programmes for AI.
Conclusions
A clinical trial was carried out to monitor vaccine-induced
HI titres, vaccination coverage and the number of
outbreaks of HPAI H5 in poultry flocks. The trial was only
small-scale, and this prevents the drawing of conclusions
about the effectiveness of vaccination in AI control in
Indonesia. Nevertheless, valuable experience was obtained
in the operation of veterinary services, sample handling,
quality assurance of laboratory testing, and the
implementation of a DIVA surveillance strategy using
sentinel birds that were not vaccinated against AI. The
results and experiences of this trial may help to develop
and improve future surveillance and control strategies in
Indonesia and in other countries in the region.
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Étude de terrain pour évaluer l’efficacité de la vaccination 
contre l’influenza aviaire en Indonésie
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S. Mudjiartiningsih, I. Dharmayanti, E. Sawitri Siregar, I. Claassen, 
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Résumé
Une étude de terrain a été réalisée afin de déterminer l’efficacité de la
vaccination contre la souche H5N1 du virus de l’influenza aviaire hautement
pathogène (IAHP) en Indonésie. L’essai clinique, de portée limitée et basé sur un
prototype, a porté sur deux groupes de poulets, le premier comprenant des
cheptels traités suivant une procédure standardisée et ayant reçu au moins deux
doses vaccinales d’un vaccin H5N1 sélectionné, et le second (groupe de
contrôle) comprenant des cheptels traités suivant des procédures non
standardisées décidées par l’éleveur. Chaque groupe consistait en six cheptels
de poules pondeuses ou de poulets autochtones. Les titres d’anticorps inhibant
l’hémagglutination (IH) ont été déterminés en se basant sur un échantillonnage
régulier ; la surveillance du foyer reposait sur l’utilisation d’oiseaux sentinelles
non vaccinés contre l’influenza aviaire. Après trois vaccinations, le groupe traité
présentait des titres élevés d’anticorps, avec près de 90 % des poules
pondeuses exhibant un titre d’anticorps IH supérieur à 40. Bien qu’aucune
conclusion ne puisse être tirée quant à une éventuelle diminution de la
transmission virale, il a été constaté que 11 élevages sont restés indemnes
durant la période d’observation ; en outre, l’étude a montré la faisabilité d’un
programme de surveillance fondé sur la différenciation entre animaux infectés et
animaux vaccinés (DIVA).
Mots-clés
Différenciation entre animaux infectés et animaux vaccinés (DIVA) – Indonésie –
Influenza aviaire hautement pathogène – Oiseau sentinelle non vacciné contre l’influenza
aviaire – Surveillance – Vaccination.
Ensayos sobre el terreno para evaluar la eficacia de la vacunación
contra la influenza aviar en Indonesia
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Resumen
Los autores describen un estudio sobre el terreno realizado en Indonesia para
determinar la eficacia de la vacunación contra la cepa H5N1 del virus de la
influenza aviar altamente patógena. Se llevó a cabo un ensayo clínico limitado,
con carácter experimental, utilizando un grupo de tratamiento normalizado, en el
que las bandadas fueron vacunadas como mínimo dos veces con una vacuna
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